Carotuximab
Based on 1 publication(s) in Google Scholar
Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions.
For research use only. We do not sell to patients.
- Purity : 99.059%
- CAS No.: 1268714-50-6
- Molecular Weight:144.8 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Carotuximab
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
Carotuximab (TRC105; 300 μg/mL; pretreatment 1 h, and then co-cultured for 12 h) reduces the 7-Ketocholesterol-induced endoglin (Eng) protein levels and pSmad1/5 and pSmad2/3 signaling in human aortic endothelial cells (HAoECs). Carotuximab mediated blockage of Eng prevented 7-Ketocholesterol-induced adhesion and transmigration of monocytes through endothelial monolayers[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human aortic endothelial cells (HAoECs)
-
Concentration:300 μg/mL
-
Incubation Time:Pretreatment 1 h, and then co-cultured for 12 h
-
Result:Reduced the 7-Ketocholesterol-induced Eng protein levels and pSmad1/5 and pSmad2/3 signaling.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NSG (NOD.Cg-Prkdcscid Il2rg
tm1Wjl /SzJ; 7-8 weeks) injected with primary AML-0032 cells[2] -
Dosage:2 mg/kg
-
Administration:i.v; every 3 days; for 8 weeks
-
Result:Along with Decitabine resulted in a more durable anti-leukemic effect in AML xenografts.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
P17813
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1X106 HepG2 cells with Carotuximab (HY-P99494, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. AF 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1268714-50-6
-
Appearance Liquid
-
Molecular Weight 144.8 kDa
-
Color Colorless to light yellow
-
SMILES
[Carotuximab]
-
Synonyms
TRC105; DE-122
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Neurodegener
Endothelium-specific endoglin triggers astrocyte reactivity via extracellular vesicles in a mouse model of Alzheimer's disease. [Abstract]2025 Jul 23;20(1):84. PMID: 40702549
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. [Content Brief]
[2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Carotuximab Related Classifications
HY-P99494 Related Classifications
Powered by Bioz